Form 4: Acrivon Therapeutics Executives Report Changes in Beneficial Ownership

Peter Blume-Jensen, President and CEO, and Kristina Masson, EVP Business Operations, report changes in their beneficial ownership of Acrivon Therapeutics, Inc. stock due to tax withholding upon vesting of restricted stock units.

Summary

• Peter Blume-Jensen, President and CEO of Acrivon Therapeutics, and Kristina Masson, EVP Business Operations, filed Form 4 documents detailing changes in their beneficial ownership of the company's stock.
• The changes resulted from shares being withheld by Acrivon Therapeutics to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units on May 14, 2025.
• Blume-Jensen had 59,766 shares withheld at a price of $1.14, resulting in him directly owning 2,226,015 shares.
• Masson had 491 shares withheld at a price of $1.14, resulting in her indirectly owning 315,686 shares.
• Both Blume-Jensen and Masson disclaim beneficial ownership of the securities held by their spouse, except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing changes in stock ownership due to routine tax withholding. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their potential impact on stock ownership.

Stakeholder Impact

• The changes in ownership are unlikely to have a significant impact on stakeholders, as they are related to routine tax withholding.

Key Dates

Keywords

Acrivon Therapeutics, Beneficial Ownership, Form 4, Blume-Jensen, Masson, Tax Withholding, Restricted Stock Units, ACRV